Copyright
©The Author(s) 2021.
World J Transplant. Sep 18, 2021; 11(9): 356-371
Published online Sep 18, 2021. doi: 10.5500/wjt.v11.i9.356
Published online Sep 18, 2021. doi: 10.5500/wjt.v11.i9.356
Ref. | Total cases | Total daily dose, mg (number of cases) at time of diagnosis of periostitis | Duration of therapy, mo (number of cases) | Voriconazole trough (1-5.5 mg/L, normal range) at the time of diagnosis of periostitis | Immunocompromised state (number of cases) | Indication of voriconazole therapy (number of cases) | Serum ALP (normal range U/L) | Bone ALP isoenzyme, (normal range U/L) | Plasma fluoride level, (normal range) | Imaging performed | Sites of bony involvement | Resolution of symptoms following voriconazole discontinuation (number of cases) |
[5] | 5 | 400 (5) | 15; 16; 26; 6; 21 | N/A; N/A; N/A; N/A; N/A | Lung transplant (5) | Antifungal prophylaxis (5) | 726 (31-103); 531; 404; 212; 111 | 263 (12-84); 300; N/A; N/A; N/A | N/A; N/A; N/A; N/A; N/A | X-ray, bone scan | Tibiae, fibulae, femurs, ulnae, radii, shoulders, scapulae, sacroiliac joints, ischia, humeri, clavicles, manubrium, ribs, ankles | Within 2 wk (1); Within 3 d (1); Within 1 wk (1); N/A (2) |
[6] | 1 | N/A | 1 | N/A | Allogeneic stem cell transplant | Antifungal prophylaxis | Elevated | N/A | N/A | X-ray, MRI | Radius, metatarsals, fibulae, tibiae, calcaneus | Within 2 mo |
[7] | 1 | 400 | 31 | N/A | Lung transplant | Antifungal prophylaxis | 433 (40-125) | 188 (20/71) | N/A | X-ray, CT scan, bone scan | hand phalanges, ribs | Within 1 mo |
[8] | 5 | 200 (1); N/A (4) | 30 (1); N/A (4) | N/A | Lung transplant (5) | Antifungal prophylaxis (3); N/A (2) | N/A | N/A | N/A | X-ray, CT scan, bone scan | hand phalanges, clavicles, humerus, scapula, ribs, femur, knee, pubic rami, sacral iliac joint | N/A (5) |
[9] | 1 | N/A | N/A | N/A | Lung transplant | N/A | N/A | N/A | N/A | X-ray | Multiple phalanges, ulnar shaft | Itraconazole replacement |
[10] | 1 | 1200 | 6 | 0.77 | Acute myelogenous Leukemia | Disseminated Fusarium infection | 525 (45-277) | 351 (4-110) | 24.3 (1-4 µmol/L) | X-ray, bone scan | Hands, forearms, humeri, femurs, pelvis, knee, feet | Improvement within 1 wk, complete resolution within 3 wk |
[11] | 6 | 400 (5); NA (1) | 6; 7; 53; 16; 16; 21 | N/A; 0.3; 2.8; 2.1; 1.0; 5.0 | Heart transplant (1); Lung transplant (3); Kidney transplant (1); Stem cell transplant (1) | Invasive pulmonary aspergillosis (1); N/A (5) | 521 (50-130); 361; 323; 243; 178; 229 | N/A; 268 (12-42); N/A; N/A; N/A; N/A | 20.7 (1-4 µmol/L); 27; 11.4; 7.5; 15.9; 13.2 | X-ray, bone scan | Fingers, wrists, elbows, legs, feet, ribs | Within 2 mo (2); Itraconazole replacement, improvement within 1 month (1); N/A (3) |
[12] | 1 | N/A | 9 | N/A | Heart transplant | Invasive Pulmonary aspergillosis | 280 | N/A | N/A | CT scan, bone scan | Ribs, sternum, humerus, forearm, femur, tibia, spine | N/A |
[13] | 1 | 400 | 1.5 | N/A | Liver transplant | Cerebral Aspergillus infection | 420 (30-120) | N/A | 10.2 (1-4 µmol/L) | X-ray, bone scan | Femur, tibia, fibula, radius, ulna, ribs, scapulae | Amphotericin B replacement, rapid resolution |
[14] | 1 | N/A | 12 | N/A | Allogenic stem cell transplant | Invasive Aspergillus sinusitis and lung infection | 475 (39-117) | 152 (7-22) | N/A | X-ray, bone scan | Phalanges, elbows, humerus, femur | Within 1 wk |
[15] | 3 | N/A (3) | 3.3; 6; 7.5 | N/A; N/A; N/A | Allogeneic stem cell transplant (3) | NA (3) | 195 (35-104); 384; 202 | N/A; N/A; N/A | N/A; 363 (<30 µg/L); 316 | X-ray, CT scan, bone scan | Entire skeleton, spine, pelvis, hands, phalanges | Within 4 d (1); NA (2) |
[16] | 1 | N/A | 5 | N/A | Heart transplant | Invasive pulmonary aspergillosis | 304 (31-95) | 90.8 (5.6-29 µg/L) | N/A | X-ray, CT scan, bone scan | Humerus, femur, ribs | Improvement within 2 wk |
[17] | 1 | N/A | 4 | N/A | N/A | Fungal endophthalmitis | N/A | N/A | N/A | X-ray, bone scan | Radial and pretibial diaphysis, radius, ulna, tibia, fibula | Within 5 d |
[18] | 2 | N/A (2) | 5 (1); N/A (1) | N/A | Heart Transplant (1); Stem Cell Transplant (1) | Antifungal prophylaxis (heart transplant); NA (stem cell transplant) | 304 (29-111); 245 | N/A; N/A | N/A; N/A | X-ray, CT scan, bone scan | Ribs, clavicles, humeri, radii, ulnae, femurs, tibia, metacarpals, phalanges | N/A |
[19] | 1 | 400 | 11 | N/A | Granulomatosis with Polyangiitis | Invasive pulmonary aspergillosis | 464 | N/A | N/A | X-ray, CT scan | Femur | Improvement within 2 d, resolution within 1 wk; posaconazole replacement |
[20] | 1 | N/A | 6 | 2.1 | Chronic granulomatous disease | Aspergillus knee septic arthritis | 380 (54-130) | N/A | 133 (< 20 µg/L) | X-ray, bone scan | Ribs, clavicles, humerus, tibia | Posaconazole replacement, improvement within 2 wk |
[21] | 1 | 400 | 9 | N/A | Lung transplant | Pulmonary aspergillosis | 359 (40-150) | N/A | N/A | CT | Scapulae, ribs, radius, ulna | N/A |
[22] | 1 | 600 | 4 | 3 | Mixed connected tissue disorder (overlap syndrome) | Pulmonary aspergillosis | 1060 (115-359) | 89.3 (3.8-22.6 µg/L) | 24.9 (1-4 µmol/L) | CT, MRI, bone scan | Scapulae, ribs, femurs | Within 3 wk |
[23] | 21 | 800; 500; 600; 1300; 700; 800; 500; 700; 500; 700; 700; 1100; 900; 700; 900; 700; 900; 900; 800; 700; 1000 | 7; 7.3; 5.5; 5; 5.5; 6.6; 4.9; 5.3; 4.6; 5; 4; 4.8; 5.5; 5.5; 6.3; 5.9; 7.5; 6.8; 5; 4.7 | 1.1; 2.3; 3.3; 4; 1.4; 2.6; 3; 3.8; 1.6; 1.5; 5.4; 1.3; 4.2; 1.5; 0.5; 1.5; 3.2; 2.5; 0.5; 2.5; 2 | Malignancy (2); DM (2); CKD (1); None (16) | Exserohilum rostratum, or Aspergillus fumigatus meningitis (contaminated methylprednisolone acetate injection) | 114 (27-120); 281; 362; 362; 452; 226; 168; 221; 97; 155; 202; 848; 208; 238; 123; 277; 442; 244; 231; 256; 228 | N/A | 11.05 (< 5.26 µmol/L); 10.53; 10.0; 14.74; 14.74; 13.16; 0.0; 12.63; 12.11; 14.21; 18.95; 16.84; 14.21; 10.53; 13.69; 8.42; 17.90; 8.95; 21.06; 10.53; 14.21 | Bone scan | Radius, ulna, tibia, fibula, clavicle, scapula, femur, ribs | 2 wk to 5 mo (8); residual pain (2); 5/10 with symptom improvement in 2-8 wk following dose reduction |
[24] | 1 | N/A | N/A | N/A | Lung transplant | Cladosporium pneumonia | elevated | N/A | N/A | X-ray | Hands, knees, feet | Itraconazole replacement, improvement over hospital course |
[25] | 1 | N/A | 12 | N/A | Acute Myelogenous Leukemia | Fungal sinusitis | N/A | N/A | N/A | X-ray, CT scan, MRI, Bone scan | Clavicle, humerus, rib | Less than 2 wk |
[26] | 1 | 800 | 3 | 4.1 | Liver Transplant | Aspergillus brain abscess | N/A | N/A | 16.3 (0.3-2.2 µmol/L) | X-ray | Radius, humerus, scapulae, ribs, appendicular skeleton | N/A |
[27] | 1 | 8 mg/kg | 36 | N/A | Mixed connective tissue disease | Extra-pulmonary histoplasmosis | 585 (35-104) | N/A | N/A | X-ray, SPECT/CT scan, bone scan | Radius, ulna, scapulae, femur, shoulders, spine, knees, ankle | N/A |
[28] | 1 | 400 | 4 | N/A | Allogeneic stem cell transplant | Fungal pneumonia | N/A | N/A | N/A | Bone scan | Clavicle, rib, hip, femur, tibia, fibula | Within 4 d |
[29] | 1 (14-year-old) | N/A | N/A | N/A | Lung transplant | N/A | N/A | N/A | N/A | X-ray, Bone scan | Phlanges, metatarsals, tibia and long bones, clavicles, scapula, sternum, pelvic bones | N/A |
[30] | 1 | 400 | 5 | N/A | Lung transplant | Antifungal therapy for abnormal bronchoalveolar lavage | 332 (no normal range) | N/A | N/A | X-ray, MRI | Hips | Itraconazole replacement; improvement within 2 wk, resolution within 4 wk |
[31] | 1 | 600 | 10 | N/A | T-cell prolymphocytic leukemia | Cerebral histoplasmosis | 200 (25-100) | N/A | N/A | X-ray, Bone scan | Clavicles, ribs, tibia, fibula | Within 2 d |
[32] | 1 | N/A | 2 | 3.9 | Liver transplant | Scedosporium brain abscess | N/A | N/A | Elevated | N/A | N/A | Posaconazole replacement, resolution |
[33] | 1 | 400 | N/A | N/A | Heart transplant | Pulmonary aspergillosis | 323 (40-115) | N/A | 0.15 (0.02-0.08 mg/dL) | X-ray | Humerus | Improvement within 5 d, resolution within 2 mo |
[34] | 1 | 800 | 3 | 4.1 | Liver transplant | Aspergillus brain abscesses | N/A | N/A | 16.3 (0.3-2.2 µmol/L) | X-ray, Bone scan | Radius, humerus shafts, scapulae | Resolved rapidly after cessation of voriconazole |
[35] | 3 | 400; 400; 400 | 3.3 (1); 6.5 (1) N/A (1) | NA (3) | Lung transplant; stem cell transplant; liver transplant | Fungal infection (1); fungal pneumonia (2) | 215 (0-140); 181-501; 500-1000 | N/A | N/A | CT scan | Sternum, vertebrae, ribs, scapulae, appendicular skeleton, ribs | N/A |
[36] | 1 | N/A | N/A | N/A | Lung transplant | Pulmonary aspergillosis | 277 (no normal range) | N/A | N/A | Bone scan, FDG-PET, CT scan | Ribs, clavicle, acetabulum, hips | N/A |
[37] | 1 (3-mo-old infant) | N/A | 4.5 | N/A | Stem cell transplant | Disseminated aspergillosis | 2,416 (95-380) | 1,581 (43-208) | 23.8 (1-4 µmol/L) | X-ray | Femur, tibia, fibula, | Posaconazole replacement; improvement within 2 d, resolution within 1 wk |
[38] | 1 | N/A | 36 | N/A | 0 | Candida glabrata abdominal aortic graft infection | N/A | 129 (0-20 µg/L) | 23.6 (1-4 µmol/L) | X-ray, Bone scan | Ribs, humeri, tibiae, Elbow, hand, carpometacarpal joint, | Within 3 wk |
[39] | 2 | 800 (1); NA (1) | 2 (1); 7 (1) | N/A (2) | Liver transplant (1); heart transplant (1) | Scedosporium brain abscess (2) | N/A | N/A | > 24 (1-4 µmol/L); 26 | X-ray, Bone scan | Sternoclavicular joints, elbows, wrists, hands, knees, ankles, feet, tibia, fibula, bilateral hip, ribs, spine, scapulae, clavicles acetabula femur, metatarsals | Posaconazole replacement, improvement in several weeks (1) |
[40] | 1 | N/A | 6 | Therapeutic | Stem cell transplantation | Invasive fungal lung infection | 341 (40-125) | N/A | N/A | MRI, X-ray | Hand phalanges | Improvement within 1 wk |
[41] | 1 | 200 | 4.4 | N/A | Stem cell transplantation | N/A | normal | N/A | N/A | X-ray, CT scan, Bone scan | Tibiae, finger phalanges, malleolus | Itraconazole replacement, resolution within 4 mo |
[42] | 1 | 600 | 10 | 4 | Granulomatosis with polyangiitis | pulmonary aspergillosis | > 1,000 (< 130) | N/A | 278 (< 50 µg/L) | X-ray, CT scan, Bone scan | Phlanges, radius, ulna, metacarpals, tibia, ribs, femur | Rapid improvement |
[43] | 1 | 400 | 48 mo | N/A | Lung transplant | Pulmonary aspergillosis | 673 (35-125) | 203 (0-20 µg/L) | N/A | X-ray, MRI, Bone scan | Metacarpals, phalanges, midfeet, femurs, pubic bone, acetabula, radius, ulna, humeral heads, ribs, clavicles, skull | Improvement within 3 mo |
[44] | 1 | 800 | 3 | 3.22 | Lung transplant | N/A | 4.71 (0.92-2.15 microkat/L) | N/A | N/A | Bone Scan | Fingers, humeri, scapula, elbows, femurs, tibiae, ribs | Within 5 d |
[45] | 1 | 600 | 7 | N/A | DM | Aspergillus skull bone osteomyelitis | N/A | N/A | N/A | X-ray, Bone scan | Extremities, ribs, and spine | Resolved |
[46] | 1 | N/A | N/A | N/A | Stem cell transplant | N/A | N/A | N/A | N/A | X-ray, CT, bone scan | Clavicle, humeri, scapulae, ribs, femurs | N/A |
[47] | 1 | 700 | 3 | 1.9 | Renal transplant | Pulmonary aspergillosis | N/A | N/A | 68 (1-4 µmol/L) | SPECT, bone scan | Knees, clavicles | Within 48 h |
[48] | 2 | NA (1); 600 (1) | 3 (1); 17 (1) | N/A; N/A | Lung transplant; lung transplant | Antifungal prophylaxis | N/A; N/A | N/A; N/A | N/A; N/A | X-ray, bone scan | Fingers, toes, ulnar bones, humeri, shoulders, femurs, tibia | Within 1 wk; Within 10 d |
[49] | 1 | 1200 | 4 | Within recommended range (no value provided) | Stem cell transplant | Pulmonary aspergillosis | 457 (40-130) | N/A | N/A | SPECT | Skull bones, pelvic bones, femurs, humerus | Switched to Posaconazole; Within 3 wk |
[50] | 1 | N/A | 96 | N/A | Lung transplant | Antifungal Prophylaxis | 724 (34-123) | N/A | N/A | X-ray | Hands, wrists | > 7 mo |
[51] | 1 | 1200 | 4 | 9.9 | 0 | Invasive aspergillosis (lung, brain)-post-influenza and pneumococcal infection | 1900 (no normal range) | N/A | N/A | Single-photon emission CT | Extremities | Resolved |
[52] | 1 | 100 | 6 | N/A | 0 | Aspergillus sinusitis and brain abscess | 1495 (4-147) | N/A | 5.3 (1-4 µmol/L) | X-ray, bone scan | Hands, ankles, and foot | 2 mo |
[53] | 1 | 400 | 48 | N/A | Stem cell transplant | Antifungal Prophylaxis | 144 (35-104) | N/A | N/A | X-ray, bone scan | Tibia, fibula | N/A |
Type of patients | Median voriconazole daily dose, (interquartile range), and number of cases | Median duration of voriconazole therapy in months, (interquartile range), number of cases months | Median voriconazole trough concentration in mg/L, number of cases |
All patients | 600 mg, (400-800 mg), 59 patients[5,7,8,10,11,13,19,21-23,26,28,30,31,33-35,42-45,47-49,51-53] | 6 mo, (4.6 – 10 mo), 77 patients[5-8,10-16,18-23,26-28,30-32,35,38-45,47-53] | 2.4 mg/L, 38 patients[10,11,20,22,23,26,32,34,42,44,47,51] |
Solid organ transplants | 400 mg, (400-450 mg), 24 patients[5,7,8,11,13,21,26,30,33-35,39,43,44,47,48] | 7 mo (3 – 17 mo), 30 patients[5,7,8,11-13,16,18,21,26,30,32,35,39,43-44,47,48,50] | 3.22 mg/L, 9 patients[11,26,32,34,44,47] |
Hematologic malignancy and hematopoietic stem cell transplants | 400 mg, (400-750 mg), 8 patients[10,11,28,31,35,49,53] | 6 mo (4.3–10.5 mo), 16 patients[6,10,11,14,15,28,31,35,37,40,41,49,53] | 0.885 mg/L, 2 patients[10,11] |
Immunocompetent hosts | 700 mg, (700-875 mg), 18 patients[23,51,52] | 5.6 mo, (4.9–6.8 mo), 18 patients[23,38,51,52] | 2.5 mg/L, 17 patients[23,51] |
- Citation: Guarascio AJ, Bhanot N, Min Z. Voriconazole-associated periostitis: Pathophysiology, risk factors, clinical manifestations, diagnosis, and management. World J Transplant 2021; 11(9): 356-371
- URL: https://www.wjgnet.com/2220-3230/full/v11/i9/356.htm
- DOI: https://dx.doi.org/10.5500/wjt.v11.i9.356